An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma

被引:6
|
作者
Chen, Xilang [1 ,2 ]
Sun, Mengyu [3 ]
Feng, Weibo [1 ,2 ]
Chen, Jie [1 ,2 ]
Ji, Xiaoyu [3 ]
Xie, Meng [3 ]
Huang, Wenjie [3 ]
Chen, Xiaoping [3 ]
Zhang, Bixiang [3 ]
Nie, Yongzhan [1 ]
Fan, Daiming [1 ]
Wu, Kaichun [1 ,2 ]
Xia, Limin [1 ,2 ,3 ]
机构
[1] Fourth Mil Med Univ, State Key Lab Canc Biol, Natl Clin Res Ctr Digest Dis, Xian, Shaanxi, Peoples R China
[2] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian, Shaanxi, Peoples R China
[3] Huazhong Univ Sci & Technol, Tongji Hosp, Inst Liver & Gastrointestinal Dis, Dept Gastroenterol,Tongji Med Coll,Hubei Key Lab, Wuhan, Hubei, Peoples R China
基金
中国国家自然科学基金;
关键词
hepatocellular carcinoma; cuproptosis; lncRNAs; prognostic signature; immune infiltration; CANCER; COPPER; PROLIFERATION;
D O I
10.3389/fgene.2023.1056000
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: Cuproptosis is a newly defined form of cell death, whether cuproptosis involved in hepatocellular carcinoma (HCC) remains elusive. Method: We obtained patients' RNA expression data and follow-up information from University of California Santa Cruz (UCSC) and The Cancer Genome Atlas (TCGA). We analyzed the mRNA level of Cuproptosis-related genes (CRGs) and performed univariate Cox analysis. Liver hepatocellular carcinoma (LIHC) was chosen for further investigation. Real-Time quantitative PCR (RT-qPCR), Western blotting (WB), Immunohistochemical (IHC), and Transwell assays were used to determine expression patterns and functions of CRGs in LIHC. Next, we identified CRGs-related lncRNAs (CRLs) and differentially expressed CRLs between HCC and normal cases. Univariate Cox analysis, least absolute shrinkage selection operator (LASSO) analysis and Cox regression analysis were used to construct the prognostic model. Univariate and multivariate Cox analysis was used to assess whether the risk model can act as an independent risk factor of overall survival duration. Different risk groups performed immune correlation analysis, tumor mutation burden (TMB), and Gene Set Enrichment Analysis (GSEA) analysis were performed in different risk groups. Finally, we assessed the performance of the predictive model in drug sensitivity. Results: CRGs expression levels have significant differences between tumor and normal tissues. High expression of Dihydrolipoamide S-Acetyltransferase (DLAT) correlated to metastasis of HCC cells and indicated poor prognosis for HCC patients. Our prognostic model consisted of four cuproptosis-related lncRNA (AC011476.3, AC026412.3, NRAV, MKLN1-AS). The prognostic model performed well in predicting survival rates. The results from Cox regression analysis suggested that risk score can serve as an independent prognostic element for survival durations. Survival analysis revealed that low risk patients have extended survival periods compared with those with high risk. The results of the immune analysis indicated that risk score has a positive correlation with B cell and CD4(+) T cell Th2, while has a negative relationship with endothelial cell and hematopoietic cells. Besides, immune checkpoint genes have higher expression folds in the high-risk set than in the low-risk set. The high-risk group had higher rates of genetic mutation than the low-risk set while having a shorter survival time. GSEA revealed the signaling pathways enriched in the high-risk group were mostly immune-related, while metabolic-related pathways were enriched in the low-risk group. Drugs sensitivity analysis indicated that our model has the ability to predict the efficacy of clinical treatment. Conclusion: The Cuproptosis-related lncRNAs prognostic formula is a novel predictor of HCC patients' prognosis and drug sensitivity.
引用
收藏
页数:20
相关论文
共 50 条
  • [21] Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs
    Zhang, Xu
    Ye, Zhiqiang
    Xiao, Guohong
    He, Ting
    COMPUTERS IN BIOLOGY AND MEDICINE, 2023, 159
  • [22] A novel cuproptosis-related prognostic lncRNA signature for predicting immune and drug therapy response in hepatocellular carcinoma
    Chen, Shujia
    Liu, Peiyan
    Zhao, Lili
    Han, Ping
    Liu, Jie
    Yang, Hang
    Li, Jia
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [23] Cuproptosis-related LncRNAs signature as biomarker of prognosis and immune infiltration in pancreatic cancer
    Chen, Hui
    Yu, Yang
    Zhou, Lei
    Chen, Junliang
    Li, Zeyu
    Tan, Xiaodong
    FRONTIERS IN GENETICS, 2023, 14
  • [24] A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma
    Liu, Yanqing
    Jiang, Jianshuai
    CANCER BIOMARKERS, 2023, 37 (01) : 13 - 26
  • [25] Comprehensive analysis of cuproptosis-related lncRNAs signature to predict prognosis in bladder urothelial carcinoma
    Zhu, Shusheng
    Li, Houying
    Fan, Yanpeng
    Tang, Chao
    BMC UROLOGY, 2023, 23 (01)
  • [26] Comprehensive analysis of cuproptosis-related lncRNAs signature to predict prognosis in bladder urothelial carcinoma
    Shusheng Zhu
    Houying Li
    Yanpeng Fan
    Chao Tang
    BMC Urology, 23
  • [27] A novel cuproptosis-related lncRNAs signature predicts prognosis in bladder cancer
    Wu, Lingfeng
    Chen, Wei
    Cao, Yifang
    Chen, Bin
    He, Yi
    Wang, Xueping
    AGING-US, 2023, 15 (13): : 6445 - 6466
  • [28] Cuproptosis-related lncRNAs predict the prognosis and immune response in hepatocellular carcinoma
    Qiongyue Zhang
    Yan Huang
    Yu Xia
    Yumeng Liu
    Jianhe Gan
    Clinical and Experimental Medicine, 2023, 23 : 2051 - 2064
  • [29] Cuproptosis-related lncRNAs predict the prognosis and immune response in hepatocellular carcinoma
    Zhang, Qiongyue
    Huang, Yan
    Xia, Yu
    Liu, Yumeng
    Gan, Jianhe
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (06) : 2051 - 2064
  • [30] Crosstalk of cuproptosis-related prognostic signature and competing endogenous RNAs regulation in hepatocellular carcinoma
    Zhu, Jun
    Wang, Jingyan
    Liu, Hong
    Lei, Tong
    Yang, Jiankang
    Lan, Sheng
    Jian, Haokun
    Fang, Hanlu
    Zhang, Yu
    Ren, Kuiwu
    Zhong, Fei
    AGING-US, 2023, 15 (23): : 13901 - 13919